Trials / Completed
CompletedNCT00092599
Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 410 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate patients who have coronary heart disease to determine if an investigational drug will further lower cholesterol when taken in combination with an approved cholesterol lowering medication.
Detailed description
The duration of treatment is 10 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0653, ezetimibe | |
| DRUG | Comparator: ezetimibe, placebo |
Timeline
- Start date
- 2003-02-01
- Primary completion
- 2004-06-01
- Completion
- 2004-07-01
- First posted
- 2004-09-27
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00092599. Inclusion in this directory is not an endorsement.